RenovoRx Inc (RNXT)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$1.15

-0.10 (-8.00%)

Market Cap: $56.41M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

76%(16/21)

Avg Surprise

+3.78%

Streak

10 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.05

Range$-0.07 - $-0.03

2 analysts

EPS RevisionsNo revisions (7d)No revisions (30d)

EPS Estimate DriftChange to current

90d ago$-0.08+37.5%

60d ago$-0.07+33.3%

30d ago$-0.07+33.3%

7d ago$-0.03-66.7%

Current$-0.05

Revenue Consensus

$1M

Range$1M - $1M

4 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.07

Range$-0.07 - $-0.07

1 analysts

Revenue Consensus

$2M

Range$1M - $2M

4 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.07	$-0.07 - $-0.07	-	-	1	-	-
Sep 30, 2026Sep 26EST	-	$-0.05	$-0.07 - $-0.03	-	-	2	No revisions (30d)	-
Jun 30, 2026Jun 26 Reported Aug 12, 2026Reported Aug 12	$-0.05	$-0.08	$-0.08 - $-0.07	+37.50%	Beat	2	0 1 30d	+37.5%
Mar 31, 2026Mar 26 Reported May 14, 2026Reported May 14	$-0.08	$-0.08	$-0.09 - $-0.07	+0.00%	Beat	3	2 1 30d	+0.0%
Dec 31, 2025Dec 25 Reported Mar 30, 2026Reported Mar 30	$-0.08	$-0.08	$-0.08 - $-0.08	+0.00%	Beat	3	0 1 30d	+33.3%
Sep 30, 2025Sep 25 Reported Nov 13, 2025Reported Nov 13	$-0.08	$-0.08	$-0.08 - $-0.08	+0.00%	Beat	2	0 1 30d	+20.0%
Jun 30, 2025Jun 25 Reported Aug 14, 2025Reported Aug 14	$-0.08	$-0.08	$-0.08 - $-0.08	+0.00%	Beat	2	0 1 30d	+20.0%
Mar 31, 2025Mar 25 Reported May 15, 2025Reported May 15	$-0.08	$-0.08	$-0.08 - $-0.07	+0.00%	Beat	2	2 0 30d	+73.3%
Dec 31, 2024Dec 24 Reported Mar 31, 2025Reported Mar 31	$-0.12	$-0.13	$-0.13 - $-0.12	+4.00%	Beat	2	0 1 30d	+61.3%
Sep 30, 2024Sep 24 Reported Nov 13, 2024Reported Nov 13	$-0.10	$-0.12	$-0.13 - $-0.11	+16.67%	Beat	3	No revisions (30d)	+23.1%
Jun 30, 2024Jun 24 Reported Aug 13, 2024Reported Aug 13	$-0.10	$-0.11	$-0.11 - $-0.09	+9.09%	Beat	2	No revisions (30d)	+54.5%
Mar 31, 2024Mar 24 Reported Apr 1, 2024Reported Apr 1	$-0.30	$-0.30	$-0.32 - $-0.29	+0.00%	Beat	2	1 0 30d	+16.7%
Dec 31, 2023Dec 23 Reported Mar 19, 2024Reported Mar 19	$-0.31	$-0.30	$-0.31 - $-0.30	-3.33%	Miss	3	No revisions (30d)	-34.8%
Sep 30, 2023Sep 23 Reported Nov 13, 2023Reported Nov 13	$-0.13	N/A	-	+53.57%	Beat	1	No revisions (30d)	+45.8%
Jun 30, 2023Jun 23 Reported Aug 16, 2023Reported Aug 16	$-0.22	$-0.29	$-0.29 - $-0.29	+24.14%	Beat	1	No revisions (30d)	+24.1%
Mar 31, 2023Mar 23 Reported May 15, 2023Reported May 15	$-0.36	$-0.25	$-0.25 - $-0.25	-44.00%	Miss	1	No revisions (30d)	-9.1%
Dec 31, 2022Dec 22 Reported Mar 2, 2023Reported Mar 2	$-0.23	$-0.26	$-0.26 - $-0.26	+11.54%	Beat	2	No revisions (30d)	-91.7%
Sep 30, 2022Sep 22 Reported Nov 14, 2022Reported Nov 14	$-0.24	$-0.29	$-0.31 - $-0.27	+17.24%	Beat	2	No revisions (30d)	+11.1%
Jun 30, 2022Jun 22 Reported Aug 15, 2022Reported Aug 15	$-0.29	$-0.28	$-0.28 - $-0.28	-3.57%	Miss	0	No revisions (30d)	+39.6%
Mar 31, 2022Mar 22 Reported May 16, 2022Reported May 16	$-0.33	$-0.21	$-0.25 - $-0.17	-57.14%	Miss	2	No revisions (30d)	+42.4%
Dec 31, 2021Dec 21 Reported Mar 30, 2022Reported Mar 30	$-0.12	$-0.16	$-0.18 - $-0.14	+25.00%	Beat	2	No revisions (30d)	+76.6%
Sep 30, 2021Sep 21 Reported Nov 15, 2021Reported Nov 15	$-0.27	$-0.21	$-0.29 - $-0.13	-28.57%	Miss	2	No revisions (30d)	+22.5%
Jun 30, 2021Jun 21 Reported Aug 27, 2021Reported Aug 27	$-0.48	$-0.58	-	+17.24%	Beat	-	-	-0.3%
Mar 31, 2021Mar 21 Reported Jun 30, 2021Reported Jun 30	$-0.57	$0.00	-	N/A	Miss	-	-	-
Dec 31, 2020Dec 20 Reported Mar 30, 2021Reported Mar 30	$-0.51	$0.00	-	N/A	Miss	-	-	-
Mar 31, 2020Mar 20 Reported Jun 29, 2020Reported Jun 29	$-0.35	$0.00	-	N/A	Miss	-	-	-
Dec 31, 2019Dec 19 Reported Mar 31, 2020Reported Mar 31	$-0.48	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-3.97	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	-368.40%
ROE	-125.20%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	5.74x	Quick Ratio	5.53x
Trading Statistics
Beta	0.97	Avg Volume	599.68K
52-Week High	$2.59	52-Week Low	$0.70

Technical Indicators Dashboard

Moving Averages

SMA 10$1.39

SMA 20$1.52

SMA 50$1.54

SMA 200$1.08

EMA 10$1.36

EMA 20$1.47

EMA 50$1.46

EMA 200$1.18

MACD

Line: -0.10Signal: -0.05Hist: -0.05

ADX

ADX: 29.5+DI: 12.1-DI: 34.1

Aroon & PSAR

Aroon UpN/A

Aroon Down100.0

PSAR$1.40

Bollinger Bands

Upper Band$1.86

Lower Band$1.18

%B Position4446%(Upper)

Band Width-0.05

RSI (14-Day)

Neutral

30.2

Momentum Oscillators

Stoch %K2.7

Stoch %D6.4

Williams %R-97.5

ROC (10d)-26.8%

Momentum-0.42

CCI (20d)-173.9

MFI (14d)16.8

Volatility Measures

ATR (14d)$0.14(12.2%)

StdDev (20d)0.17

Hist Vol74.8%(High)

Volume Flow

VWAP$1.19

OBV855.1K

AD Line-10.0M

CMF (20d)-0.328

Volume Metrics

Avg Vol (20d)579.0K

Vol Ratio1.6x(High)

VWMA (20d)$1.51

Pivot Points

R3$1.37

R2$1.34

R1$1.30

Pivot Point$1.27

S1$1.23

S2$1.20

S3$1.16

Advanced Oscillators

TSI-19.07

Ultimate Osc30.3

KST-104.57

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$909,000	$563,000	$238,000	$266,000	$422,000	$197,000	$43,000	$0	$0	$0	$0	$0
Cost of Revenue	$143,000	$84,000	$28,000	$53,000	$152,000	$94,000	N/A	$0	$0	$0	N/A	$0
Gross Profit	$766,000	$479,000	$210,000	$213,000	$270,000	$103,000	$43,000	$0	$0	$0	N/A	$0

Operating Expenses	$4.12M	$3.95M	$3.73M	$3.41M	$2.95M	$3.21M	$2.67M	$2.83M	$3.03M	$2.48M	$1.78M	$2.98M
R&D	$1.20M	$1.23M	$1.52M	$1.69M	$1.43M	$1.64M	$1.58M	$1.65M	$1.54M	$1.26M	$775,000	$1.63M
SG&A	$2.92M	$2.72M	$2.22M	$1.73M	$1.52M	$1.57M	$1.10M	$1.18M	$1.49M	$1.22M	$1.00M	$1.35M
Operating Income	$-3,349,000	$-3,469,000	$-3,522,000	$-3,200,000	$-2,678,000	$-3,110,000	$-2,632,000	$-2,828,000	$-3,034,000	$-2,476,000	$-1,777,000	$-2,983,000

Interest Income	$90,000	$45,000	$75,000	$113,000	$133,000	$106,000	$85,000	$124,000	$138,000	$37,000	$11,000	$43,000
Interest Expense	$0	$52,000	$0	$0	$217,000	$0	$246,000	$0	$0	$0	$1.45M	$0
Income Before Tax	$-2,911,000	$-3,521,000	$-2,941,000	$-2,912,000	$-2,895,000	$-2,420,000	$-2,878,000	$-2,471,000	$-2,389,000	$-1,076,000	$-3,227,000	$-1,421,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-2,911,000	$-3,521,000	$-2,941,000	$-2,912,000	$-2,895,000	$-2,420,000	$-2,878,000	$-2,471,000	$-2,389,000	$-1,076,000	$-3,227,000	$-1,421,000

EBITDA	$-2,994,000	$-3,565,000	$-3,015,000	$-3,026,000	$-3,027,000	$-2,525,000	$-2,963,000	$-2,595,000	$-2,527,000	$-1,113,000	$-1,777,000	$-1,464,000
EBIT	$-2,999,000	$-3,566,000	$-3,016,000	$-3,025,000	$-3,028,000	$-2,526,000	$-2,963,000	$-2,595,000	$-2,527,000	$-1,113,000	$-1,777,000	$-1,464,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about RNXT

News

Form RW RenovoRx, Inc.

RenovoRx, Inc. has formally requested the withdrawal of its Registration Statement on Form S-3 (File No. 333-291547) from the SEC. The company states that the registration statement was never declared effective...

StreetInsider•Oct 16, 2026 6:40 AM ET10/16/26•Somewhat-Bearish

RenovoRx, Inc. SEC Filing (Oct 16, 2026)

RenovoRx, Inc. has filed an application for the withdrawal of its Registration Statement on Form S-3 (File No. 333-291547), initially filed on November 14...

Stock Titan•Oct 16, 2026 6:40 AM ET10/16/26•Neutral

RenovoRx Advances TAMP into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx announced the enrollment of the first patient in the investigator-initiated PRISM-TAMP trial, which is evaluating its Trans-Arterial Micro-Perfusion (TAMP) platform for treating borderline resectable pancreatic...

Investing News Network•Oct 7, 2026 11:09 PM ET10/7/26•Bullish

RenovoRx enrolls first patient in UVM-sponsored PRISM-TAMP trial

RenovoRx, Inc. announced the enrollment of the first patient in the PRISM-TAMP trial, an investigator-initiated study sponsored by the University of Vermont. This trial explores the company's Trans-Arterial...

StreetInsider•Oct 7, 2026 8:32 AM ET10/7/26•Bullish

A pancreatic cancer trial will test chemo near the tumor before surgery. Its first patient has enrolled.

RenovoRx announced the enrollment of the first patient in its PRISM-TAMP trial, an investigator-initiated study sponsored by the University of Vermont. This trial investigates delivering gemcitabine directly...

Stock Titan•Oct 7, 2026 8:32 AM ET10/7/26•Bullish

RNXT Valuation and Fair Value

P/E: -4.0x
P/B: 6.1x

See GNG's fair value

RNXT Profitability: Margins, ROIC and FCF

Gross margin: 84.4%
Operating margin: -368.4%
Net margin: 0.0%
ROE: -125.2%
FCF margin: -604.1%

RNXT Competitors

Company	Ticker
Pheton Holdings Ltd Class A Ordinary Shares	PTHL
Talphera Inc.	TLPH
Connect Biopharma Holdings Ltd	CNTB
Pliant Therapeutics Inc	PLRX
Gain Therapeutics Inc	GANX
Gossamer Bio Inc	GOSS
Daxor Corporation	DXR
Fractyl Health, Inc. Common Stock	GUTS

Sector: Healthcare

RNXT Analyst Ratings

Consensus: Buy
Analysts: 4
Strong Buy: 0
Buy: 4
Hold: 0
Sell: 0
Strong Sell: 0

RNXT Bull Case vs Bear Case

Bull case

RNXT grew quarterly revenue 115.4% year over year.

Bear case

RNXT beat EPS estimates in 37.5% of its last 8 reported quarters.

RNXT Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: 7.3%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.05
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 0 down

Frequently Asked Questions About RNXT

Does RNXT pay dividends?

RenovoRx Inc (RNXT) does not currently pay a regular dividend.

What is RNXT's market cap?

RenovoRx Inc (RNXT) has a market capitalization of $56.41M with a current stock price of $1.15.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In